Consensus Clinical Recommendations for the Management of Dyslipidaemia in the African Population

¹Ndjessan Jean Jacques, ²Ekou Arnaud, ³Boka Benedicte, ⁴Amelie Delphine Lagou, ⁵Ake Traboulsi, ⁶Adoubi Anicet, ⁷Ngoran Yves, ⁸Kadio Ede Martin, ⁹Angoran Ines, ¹⁰Dago Koffi, ¹¹Traore Diabey Fatoumata, ¹²Kacou JbAnzouan,¹³*Shalini Kumar, ¹⁴Isha Desai Mistry, ¹⁵Pravin Joshi
¹Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
²Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
³Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
⁴Nephrologist,The University Hospital Center of Bouake,Ivory Coast
⁵Cardiologist,PISAM Hospital, Abidjan,Ivory Coast
⁶Cardiologist, The University Hospital Center of Bouake,Ivory Coast
⁷Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
⁸Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
⁹Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
¹⁰Endocrinologist,The University Hospital Center of  Cocody, Ivory Coast
¹¹Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
¹²Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
¹³Ajanta Pharma, Mumbai, India
¹⁴Ajanta Pharma, Mumbai, India
¹⁵Ajanta Pharma, Mumbai, India

A B S T R A C T
Context: While there are many international guidelines on the management of dyslipidaemia, there is lack of clinical recommendations for the management of dyslipidaemia in the African population, considering its increasing prevalence and unique regional disparities.Objective: The objective of this consensus document was to provide original recommendations on dyslipidaemia management and to find gaps in the treatment and opportunities for improved lipid control for the population of Ivory Coast, West Africa.Design: A multidisciplinary panel of regional experts was convened and reached an original consensus on the clinical management of dyslipidaemia in the African population in February 2023.Method:A panel of 12 experts in the fields of cardiology, endocrinology, and nephrology was formed from Ivory Coast, West Africa. The panel discussed a questionnaire based on existing guidelines. Recommendations were constructed in accordance with local and regional clinical practices. Results: The panel made recommendations on the diagnosis and management of dyslipidaemia in patients at risk for diabetes and cardiovascular disease in the Ivory Coast population. Atorvastatin was recommended as a high-intensity statin to reduce low-density lipoprotein cholesterol by more than 50% of clinicians. Additionally, recommendations were made on statin therapy in patients with atherosclerotic cardiovascular disease, diabetes, and chronic kidney disease. Conclusion: Regional practitioners, in addition to adhering to dyslipidaemia-management guidelines, need to consider dietary and lifestyle behaviours when formulating management strategies for dyslipidaemia. Clinicians must work with patients to create customised therapies. Greater consensus among regional experts across Africa can create a unified approach for the entire region.
Keywords: dyslipidaemia, clinical recommendations, cardiology, endocrinology, nephrology, Atorvastatin